Anti-TG2 Antibody Liquid Formulations for Room-Temperature Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical formulations of anti-TG2 antibodies lack stability, particularly at room temperature, leading to potential loss of activity and unsuitability for intravenous or subcutaneous injection.
Innovation Solution
A stable liquid formulation comprising anti-TG2 antibodies is achieved by using a histidine buffer to maintain pH between 5.0 and 6.0, combined with arginine or arginine salts as an amino acid stabilizer, optionally with polysorbate surfactants, to ensure long-term stability and processability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TG2 antibody formulations are prepared without specific stabilizing excipients, then the formulation complexity is reduced, but the protein stability and biological activity are lost due to denaturation, aggregation or oxidation
Solution Approach 1:
The patent applies parameter changes by optimizing the pH range (5.0-6.0) and selecting specific excipient concentrations to enhance antibody stability. The histidine buffer system maintains pH within this optimal range, while arginine stabilizer concentration is carefully controlled to prevent aggregation without causing formulation complexity
Solution Approach 2:
The patent uses histidine buffer and arginine stabilizer as intermediary substances that mediate between the antibody and environmental stressors. These excipients act as protective intermediaries that prevent direct interaction between the antibody and destabilizing factors such as pH extremes, oxidation, and aggregation
2Productivity
If the antibody concentration is increased to reduce dosing volume, then the productivity is improved, but the formulation stability deteriorates due to increased aggregation and viscosity
Solution Approach 1:
The patent achieves high antibody concentrations (up to 300 mg/mL) by changing the formulation parameters - specifically using histidine buffer at pH 5.0-6.0 combined with arginine stabilizer. This parameter combination allows concentrated formulations without proportionally increasing aggregation or viscosity, thereby maintaining stability at high productivity levels
Solution Approach 2:
The patent creates a composite formulation system combining antibody, histidine buffer, and arginine stabilizer in specific ratios. This composite approach allows the components to work synergistically, where the buffer and stabilizer collectively enable high antibody concentration while maintaining formulation stability through their combined protective effects
3Ease of operation
If room temperature storage is enabled for convenience, then the ease of operation is improved, but the loss of substance increases due to accelerated degradation and aggregation
Solution Approach 1:
The patent enables room temperature storage by changing the formulation's chemical parameters - specifically using histidine buffer at pH 5.0-6.0 which creates a chemically stable environment that resists degradation at elevated temperatures. This parameter optimization allows the formulation to maintain stability without requiring refrigeration, improving ease of operation
Solution Approach 2:
The patent applies preliminary anti-action by incorporating histidine buffer and arginine stabilizer that proactively counteract degradation mechanisms before they occur. These excipients are pre-formulated to prevent aggregation and oxidation that would otherwise be accelerated at room temperature, thereby preserving antibody substance during convenient storage conditions
4Reliability
If excipients are added to stabilize the protein, then the reliability is improved, but the object-generated harmful factors increase due to potential immunogenicity and formulation incompatibility
Solution Approach 1:
The patent minimizes harmful factors by optimizing excipient selection and concentration parameters. Histidine buffer and arginine stabilizer are used at carefully controlled concentrations that provide maximum stability while minimizing immunogenicity risk. The pH range of 5.0-6.0 is specifically chosen to balance stability with reduced risk of formulation-related adverse effects
Solution Approach 2:
The patent uses simple, well-characterized excipients (histidine buffer and arginine) that are pharmacologically acceptable and have established safety profiles. These basic substances provide effective stabilization without the complexity and increased immunogenicity risk associated with more complex stabilizing systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation maintains at least 80% biological activity of the anti-TG2 antibody for over 12 months at temperatures ranging from 2 to 25°C, minimizing aggregation and acidification, and is suitable for injection.
Implementation Method 1
a buffer which keeps the pH at or about 5.0 to 6.0
Implementation Method 2
an amino acid stabilizer
Implementation Method 3
optionally a polysorbate surfactant
Data Source
AI summary
The invention relates to the field of pharmaceutical formulations. More particularly it is directed to liquid formulations comprising anti-TG2 antibodies and to methods of producing such formulations. The liquid formulations according to the invention are stable upon storage at a temperature from about 2 to 25° C. for an appropriate period of time.